Biological Agents in Familial Mediterranean Fever Focusing on Colchicine Resistance and Amyloidosis

被引:9
|
作者
Sozeri, Betul [1 ]
Kasapcopur, Ozgur [2 ]
机构
[1] Ege Univ, Fac Med, Dept Pediat, Izmir, Turkey
[2] Istanbul Univ, Cerrahpasa Med Fac, Dept Pediat, Istanbul, Turkey
关键词
Colchicine resistance; Familial Mediterranean fever; therapy; SUBCLINICAL INFLAMMATION; PERIODIC SYNDROME; INTERFERON-ALPHA; TURKISH PATIENTS; DOUBLE-BLIND; CANAKINUMAB; ARTHRITIS; EFFICACY; PROTEIN; TRIAL;
D O I
10.2174/0929867322666150311152300
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Familial Mediterranean fever (FMF) is the most common hereditary autoinflammatory syndrome. FMF is caused by mutations in the MEFV gene which encodes the pyrin protein. FMF is characterized by sporadic, paroxysmal attacks of fever and serosal inflammation, lasting 1-3 days. Patients may develop renal amyloidosis. Colchicine prevents attacks and renal amyloidosis. 5% to 10% of the patients with FMF are resistant or intolerant to colchicine. Colchicine resistant patients may receive biological therapies. Anti-interleukin-1 drugs are the most important agents of biological treatments. In this review, colchicine resistance and treatment options will be evaluated.
引用
收藏
页码:1986 / 1991
页数:6
相关论文
共 50 条
  • [41] PREDICT-crFMF score: A novel model for predicting colchicine resistance in children with familial Mediterranean fever
    Ayaz, Nuray Aktay
    Demirkan, Fatma Gul
    Coskuner, Taner
    Demir, Ferhat
    Tanatar, Ayse
    cakan, Mustafa
    Karadag, Serife Gul
    Yener, Gulcin Otar
    Ozturk, Kubra
    Baglan, Esra
    cakmak, Figen
    caglayan, Senguel
    Ozdel, Semanur
    Ulu, Kadir
    Sozeri, Betul
    Sonmez, Hafize Emine
    MODERN RHEUMATOLOGY, 2023, 34 (01) : 220 - 225
  • [42] IL-1β Biological Treatment of Familial Mediterranean Fever
    Soriano, Alessandra
    Verecchia, Elena
    Afeltra, Antonella
    Landolfi, Raffaele
    Manna, Raffaele
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2013, 45 (01) : 117 - 130
  • [43] Canakinumab for the treatment of familial Mediterranean fever
    Ozdogan, Huri
    Ugurlu, Serdal
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (05) : 393 - 404
  • [44] COLCHICINE CONCENTRATION IN LEUKOCYTES OF PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER
    CHAPPEY, O
    NIEL, E
    DERVICHIAN, M
    WAUTIER, JL
    SCHERRMANN, JM
    CATTAN, D
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (01) : 87 - 89
  • [45] The feasibility of withdrawing canakinumab in paediatric colchicine-resistant familial Mediterranean fever patients
    Sozeri, B.
    Sonmez, H. E.
    Karadag, S. G.
    Baglan, E.
    Ozturk, K.
    Cakan, M.
    Demir, F.
    Yener, G. Otar
    Ozdel, S.
    Ayaz, N. Aktay
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (05) : S118 - S123
  • [46] Colchicine is a Safe Drug in Children with Familial Mediterranean Fever
    Padeh, Shai
    Gerstein, Maya
    Berkun, Yackov
    JOURNAL OF PEDIATRICS, 2012, 161 (06) : 1142 - 1146
  • [47] Current perspectives on familial Mediterranean fever
    Guz, Galip
    Kanbay, Mehmet
    Ozturk, M. Akif
    CURRENT OPINION IN INFECTIOUS DISEASES, 2009, 22 (03) : 309 - 315
  • [48] The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever
    Lorenzo Calligaris
    Federico Marchetti
    Alberto Tommasini
    Alessandro Ventura
    European Journal of Pediatrics, 2008, 167 : 695 - 696
  • [49] Colchicine-resistant sacroiliitis in a Japanese patient with familial Mediterranean fever
    Matsumoto, Haruki
    Sumichika, Yuya
    Saito, Kenji
    Yoshida, Shuhei
    Temmoku, Jumpei
    Fujita, Yuya
    Matsuoka, Naoki
    Asano, Tomoyuki
    Sato, Shuzo
    Migita, Kiyoshi
    MODERN RHEUMATOLOGY CASE REPORTS, 2023, 8 (01) : 215 - 218
  • [50] Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents
    Eroglu, Fehime Kara
    Besbas, Nesrin
    Topaloglu, Rezan
    Ozen, Seza
    RHEUMATOLOGY INTERNATIONAL, 2015, 35 (10) : 1733 - 1737